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What is type 1 diabetes?  
Insulin-dependent diabetes mellitus (IDDM), otherwise known as type 1 diabetes, is 
currently one of the most prevalent autoimmune conditions, affecting over 30 million individuals 
worldwide (You & Henneberg, 2016). According to the American Diabetes Association, this 
number is rapidly on the rise with an estimated prediction of 40,000 new diagnoses per year in 
the United States alone (ADA; 2017).  
Under healthy conditions, the endocrine and central nervous systems intricately function 
together to maintain metabolic and glucose homeostasis throughout the body (Aronoff et al., 
2004; Raman, 2017). Following a meal, nutrients from the foods consumed are absorbed in the 
gastrointestinal (GI) tract, then into the blood stream, which leads to an increase in blood glucose 
levels, triggering the release of the hormone insulin from pancreatic islet β-cells (Scarlett & 
Schwartz, 2015). The insulin released functions to signal glucose uptake into liver, muscle, and 
fat cells where it can be stored or utilized for energy (Wilcox, 2005). In conjunction, the brain- 
centered glucoregulatory system (BCGS) receives and integrates various nutrition signals, plays 
a role in inhibiting liver glucose production, and facilitates both insulin-dependent glucose 
uptake and insulin-independent glucose disposal (Scarlett & Schwartz, 2015). In turn, these 
complex processes are able to regulate and maintain healthy levels of blood glucose. However, in 
type 1 diabetes, a combination of genetic predispositions and environmental triggers lead the 
immune system to produce autoantibodies that misperceive insulin producing β-cells as invaders 
and destroy them (Atkinson, 2012). With a widespread lack of insulin, the glucoregulatory 
system is disrupted and glucose is unable to enter cells. Instead, glucose accumulates in the 
blood stream leading to hyperglycemia, which manifests in a variety of symptoms including 
excessive hunger, thirst, and urination, unintentional weight loss, blurred vision, fatigue, 
Orton 3 
weakness, irritability, and mood changes (Mayo Clinic, 2017). If type 1 diabetes is not promptly 
recognized and treated, prolonged elevated blood glucose levels can lead to diabetic ketoacidosis 
(DKA), in which a lack of insulin provokes increased secretion of glucose from the kidney and 
liver, amino acids from muscle, and free fatty acids from adipose tissue, in turn increasing blood 
acidity, reducing blood flow, and inducing severe dehydration (Raghupathy, 2015). Merely a 
century ago, a diagnosis of T1D was fatal within weeks or months, even when following a 
strictly low carbohydrate diet, and individuals would develop DKA and their cells would be 
essentially starved of energy (Rosenfeld, 2002) Around the 1920s, however, the discovery of 
exogenous insulin, made possible by contributions from several scientists, Frederick Banting, 
Charles Best, Jon Macleod, and James Collip, changed the prognosis (Rosenfeld, 2002). With 
administration of exogenous insulin, the gap in the glucoregulatory system can by artificially 
restored, making it possible for individuals diagnosed with type 1 diabetes to live relatively long 
and healthy lives, that is, with diligent 24/7 management.  
Management  
When it comes to managing type 1 diabetes, every individual follows different protocols 
and has unique insulin requirements due to the complex nature of the condition. Therefore, 
working with an endocrinologist and diabetes educator in the management of this condition is 
important to establish and adjust treatment plans and care as needed.  
Day to day, individuals with type 1 diabetes must frequently monitor their blood glucose 
levels via finger sticks (approximately 10-15 times a day) or by subcutaneous continuous glucose 
monitoring (CGM) (National Diabetes Education Initiative, 2016). Target blood glucose ranges 
can vary based upon a variety of factors including, age, comorbid conditions, duration of 
diabetes, and other considerations; however, the ADA guidelines broadly recommend a blood 
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glucose range of 80 to 130 mg/dL pre-prandial, <180 post-prandial, and a 3-month average of 
<154 mg/dL or 7.0%, measured by a glycated hemoglobin (HbA1c) levels (2018).  
In addition to monitoring blood glucose levels, individuals must measure and count all 
carbohydrates consumed and administer intensive bolus-basal insulin therapy via either multiple 
daily injections (MDI) or a continuous subcutaneous insulin infusion (CSII) pump (ADA, 2015; 
Mianowska et al., 2011). When using MDI, individuals inject rapid or short-acting bolus doses of 
insulin prior to meals and to correct high blood glucose levels, based upon insulin to carb and 
correction factor ratios, in addition to long-acting insulin once per day (Subramanian et al., 
2016). When using CSII, individuals wear a small device that continuously administers 
preprogramed basal doses of fast-acting insulin and allows for bolus doses with meals and blood 
glucose corrections via a small cannula under the skin (Subramanian et al., 2016). For many, 
insulin pump therapy is much more flexible for daily life, as basal insulin doses can be easily 
adjusted as needed when taking into account the multitude of factors that can affect blood 
glucose levels and insulin requirements, including physical activity, stress levels, illness, other 
medications, hormone levels, weather conditions, time of day, etc. (ADA, 2015; Mianowska et 
al., 2011). With these extensive factors that can influence various aspects of type 1 diabetes 
management, achieving adequate control can be difficult and exhausting. 
Impacts on the body  
Although individuals with well-managed type 1 diabetes can live relatively long and 
healthy lives, various structural and physiological changes occur within these individuals and can 
be exacerbated by inadequately controlled blood glucose levels. It is thought that due to 
prolonged exposure to high and low blood glucose levels over time, the body undergoes 
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extensive amounts of oxidative stress leading to widespread maladaptations and increased risk 
for comorbid conditions (Arif et al., 2018; Giacco et al., 2010).  
A majority of hyperglycemia related changes that have been observed in individuals with 
type 1 diabetes occur within macro and microvasculature. Although mechanisms of these 
changes are not completely understood, research suggests that chronic inflammation and altered 
signaling for intracellular regulation of calcium and vascular endothelial growth factor (VEGF) 
may play key roles in the increased risk for development of vascular complications associated 
with type 1 diabetes (e.g. hypertension, stroke, myocardial infarction, coronary and peripheral 
artery disease) (Stehno-Bittel, 2012). Additionally, within the musculoskeletal system, several 
changes, including reduced bone mineral density and turnover, impaired skeletal muscle 
regeneration following injury, as well as altered mitochondrial structure and bioenergetics, have 
been discovered (Krause et al., 2013; Maggio et al., 2010; Monaco et al., 2018; Parajuli et al., 
2015). Because the musculoskeletal system is integral to providing structural support and 
facilitating movement, these changes can be detrimental, as they put individuals at greater risk 
for fractures, delayed injury recovery, and reduced physical performance among other negative 
impacts (Krause et al., 2013; Stehno-Bittel, 2012).  
On the other hand, acute and prolonged exposure to hypoglycemia have also been found 
to have diverse impacts on the body, primarily affecting the cardiovascular and central nervous 
systems. Principally, when it comes to the acute effects of hypoglycemia on the cardiovascular 
system, various mechanisms related to counter regulatory hormones and autonomic system 
activation lead to extensive physiological and pathophysiological changes (Yang et al., 2016). 
Electrophysiologically, T waves become inverted or decreased in magnitude, QT intervals are 
prolonged, and ST segments are depressed (Yang et al., 2016). Hemodynamically, peripheral 
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systolic blood pressure, heart rate, cardiac output, and myocardial contractility increase, while 
peripheral artery resistance and central blood pressure decrease (Yang et al., 2016). Additionally, 
prothrombotic and inflammatory effects have been found throughout the vasculature. With these 
various changes occurring in the cardiovascular system during hypoglycemia, recent research 
suggests that there may be long-term adverse consequences when it comes to prolonged 
exposure such as increased risk for cardiovascular events, dysrhythmias, and mortality (Paty, 
2015).  
In conjunction with acute cardiovascular responses, hypoglycemia impacts the central 
nervous system due to a lack of glucose in the brain, which is its primary source of fuel 
(Rooijackers, 2016). With severe decreases in blood glucose levels, brain glucose concentrations 
can become substantially lower than the average 15-20% leading to neuronal cell death, 
oxidative stress, and alterations in brain activity measured by electroencephalography (Jensen et 
al., 2014). These physiological changes can manifest in a variety of symptoms, including 
impaired cognitive function, confusion, dizziness, shakiness, stupor, etc. (Tanoli et al., 2011). 
Further, severe or extended acute hypoglycemic episodes can rapidly become life-threatening, 
provoking loss of consciousness and seizures (Jensen et al., 2014; Tanoli et al., 2011). Without 
prompt administration of subcutaneous exogenous glucagon, an unconscious, seizing individual 
with hypoglycemia can go into a coma and die (Jensen et al., 2014). Long-term, research has 
suggested that prolonged exposure to hypoglycemia can additionally generate hypoglycemia 
unawareness, recurrent hypoglycemia, memory deficits, and various neurocognitive impairments 
(Northam et al., 2001; Rooijackers, 2016).  
Due to the dynamic widespread effects of both hyper and hypoglycemia on the body, it is 
imperative for individuals with type 1 diabetes to reduce their exposure to abnormal blood 
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glucose levels and maintain euglycemia as much as possible. One of the most emphasized means 
of achieving adequate blood glucose control is regular physical activity and exercise (Riddell et 
al., 2017).  
Exercise  
Widespread positive health benefits of exercise have been elucidated extensively in 
research. For example, regular exercise across the lifespan has been associated with decreased 
risk of various conditions, such as obesity, cardiovascular disease, osteoporosis and 
osteoarthritis, some cancers, and can improve mental, heart, muscle, bone, and joint health 
(Singh, 2002; Warburton et al., 2006). For individuals with type 1 diabetes, routine exercise is 
additionally highlighted as a means of improving blood glucose control, lowering total daily 
insulin requirements via greater insulin sensitivity, and reducing risk of various complications 
previously discussed (Stehno-Bittel, 2012).  
Following exercise recommendations can be challenging, however, for individuals with 
type 1 diabetes due to increased blood glucose variability and more frequent bouts of 
hypoglycemia that are often induced by various types of activity. In a healthy individual, 
glucoregulation during moderate to high-intensity exercise is maintained, as glucose uptake at 
active muscles considerably increases, circulating insulin levels are reduced, and hepatic glucose 
production is upregulated (Camacho et al., 2005). However, in individuals with type 1 diabetes, 
glucose production is reduced due to an inadequate hepatic response and plasma insulin levels 
fail to be decreased while glucose uptake remains elevated (Camacho et al., 2005). Furthermore, 
accelerated subcutaneous insulin absorption and action have been noted with exercise in 
individuals with type 1 diabetes (Camacho et al., 2005). Consequently, these impaired 
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glucoregulatory processes lead to greater hypoglycemia risk during exercise and up to 48 hours 
following an exercise bout (Basu et al., 2014; Camacho et al., 2005).  
When comparing anaerobic versus aerobic exercise, each has slightly different impacts 
on blood glucose levels in type 1 diabetes. With anaerobic exercise, such as weight lifting, 
sprinting, and jumping, blood glucose levels often initially increase due to metabolic and 
hormonal responses (Hargreaves, 2000; Turner et al., 2015). Particularly, surges in plasma 
noradrenaline and adrenaline during anaerobic exercise have been shown to induce β- 
adrenoceptor mediated glucose release from the liver, raising blood glucose levels (Howlett et 
al., 1999). This response, however, is typically only observed with one to two sets of short- 
duration resistance exercises, while three or more sets induce more utilization of circulating 
blood glucose to sustain prolonged periods of resistance exercises (Turner et al., 2015; Yardley 
et al., 2013). In turn, with extended periods of anaerobic exercise, blood glucose levels are more 
stable and may increase or decrease only slightly, depending on intensity and duration. In 
contrast, aerobic exercise has been extensively linked to hypoglycemia both during and 
following activity.  
With aerobic exercise, the body relies primarily on free fatty acids, muscle glycogen, and 
blood glucose as fuel sources; therefore, with continued exercise, blood glucose levels steadily 
decrease (Hargreaves, 2000). Having initial blood glucose levels around 120mg/dL, within 15 
minutes of the onset of aerobic exercise, blood glucose levels begin to drop at a rate of 
approximately 1-2mg/dL/min which can rapidly increase proportional to intensity and duration 
(Tansey et al., 2006; Yardley et al., 2013). In order to increase blood glucose levels to the 
healthy range, 15g of oral glucose supplementation is necessitated every 15 minutes, however, 
during aerobic exercise this is often inadequate, leading to prolonged hypoglycemia that is 
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difficult to treat and can quickly become critical (Tansey et al., 2006). Additionally, not only 
does aerobic exercise induce rapid decreases in blood glucose during activity, it also increases 
incidence of nocturnal hypoglycemia during sleep (Tamborlane, 2007). Since counteregulatory-
hormone responses that occur with hypoglycemia are blunted during sleep, nocturnal low blood 
glucose levels can pose significant danger, as individuals do not perceive symptoms and may 
sleep through episodes, especially during deep sleep phases (Jones et al., 1998). For these 
reasons, it is a common phenomenon for individuals with type 1 diabetes to avoid exercise due to 
a fear of hypoglycemia as well as undereducation about how to manage blood glucose levels 
with the added impacts of different activity types, intensities, and durations. Therefore, it is 
essential to understand how blood glucose levels can be maintained near euglycemia during and 
post exercise in order to improve overall health, condition management, and quality of life for 
individuals with type 1 diabetes.  
Reducing blood glucose variability  
Despite the prevalence of type 1 diabetes and importance of regular exercise in overall 
health and condition management, research surrounding glycemic control and exercise is 
somewhat limited. However, several areas of focus in recent literature include insulin therapy 
modification, pre-exercise carbohydrate supplementation, order of exercise type, and the use of 
closed-loop pump technology.  
An investigative study by West and colleagues (2010) looked at the effects of 25%, 50%, 
and 75% pre-exercise rapid-acting basal insulin reductions on blood glucose level patterns both 
during and throughout a 24-hour period following 45 minutes of running at 70% of maximal 
oxygen uptake (VO2max). Neither 25% nor 50% were adequate reductions in insulin, leading to 
hypoglycemia. However, a 75% insulin reduction best preserved blood glucose levels during and 
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following aerobic exercise. In a more in-depth follow up study, West and colleagues (2011) 
administered low glycemic index carbohydrate supplementation prior to a 30, 60, 90, or 120-
minute rest period in addition to a 75% reduction in basal insulin dose prior to, during, and 3 
hours following running at 70% VO2max for 45 minutes. With both carbohydrate 
supplementation and insulin reduction, adequate blood glucose levels were most favorably 
preserved in the group that had a 30-minute rest period. Particularly, decreased carbohydrate 
oxidation and increased lipid oxidization likely contributed to sustained adequate blood glucose 
levels due to a shift toward greater dependence on fat utilization for energy (West et al., 2011). 
Although insulin adjustment and carbohydrate supplementation can diminish hypoglycemic 
episodes during and post-aerobic exercise, reduced basal insulin rates can induce hyperglycemia 
prior to exercise, which was observed in these studies, and is not favorable due to associated 
health risks. Additionally, taking the time to reduce insulin, supplement carbohydrates, and 
factor in a period of rest prior to exercise requires time, planning, and diligence, which is not 
always feasible in day to day life.  
From a different angle, another relatively recent area of interest when it comes to 
glycemia management is the order in which one performs different types of activity. Considering 
the divergent metabolic and hormone responses between anaerobic and aerobic exercise, Yardley 
et al. (2012) set out to determine whether performing aerobic prior to anaerobic exercise, or vise 
versa, has an impact on glycemic control in individuals with type 1 diabetes. In the study, a 
group of physically active individuals with adequately controlled type 1 diabetes (HbA1c = 7.1 ± 
1.0%) performed either 45 minutes of 60% VO2max running prior to 45 minutes of a resistance 
training circuit program, or in the reverse order. In the aerobic before resistance (AR) condition, 
an immediate drastic drop in plasma blood glucose levels was observed which slightly recovered 
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as resistance exercise progressed and into the first hour of recovery. In the resistance before 
aerobic (RA) condition, however, blood glucose levels were stable during the first exercises and 
more slowly decreased during aerobic exercise, maintaining euglycemia into the first hour of 
recovery. Additionally, during the 12 hours following exercise, the AR group experienced a drop 
in blood glucose around 1:00am and much lower glycemia overnight than the RA group, which 
was more stable. Although RA blood glucose levels were more stable both during and following 
the exercise program, it is important to note that the study reports an equal number of 
hypoglycemic episode between the two groups; however, RA hypoglycemic episodes were 
significantly shorter in duration than AR (48 ± 68 min; 105 ± 116 min). Due to these result, this 
study does not permit a conclusion that resistance before aerobic exercise eliminates 
hypoglycemia, but it does suggest that it may contribute to reducing the time spent in a 
hypoglycemic state.  
Although the aforementioned research focused on mediating exercise induced 
hypoglycemia generate helpful advice for individuals with type 1 diabetes, nothing can replace 
the intricate control system of healthy pancreatic β-cells when it comes to glucoregulation. Next 
best, however, is a hybrid closed-loop pump system, or artificial pancreas, which is currently one 
of the leading focuses of research when it comes to type 1 diabetes management. Closed-loop 
pump systems integrate CGM sensor readings into algorithms developed to functionally adapt 
basal insulin delivery in response to blood glucose trends and predictions analogous to that of a 
working pancreas in order to adequately maintain euglycemia. At present, many studies have 
demonstrated the efficacy of such systems under simple, controlled conditions, yet they must be 
capable of adapting to more complex scenarios and the diverse factors that influence blood 
glucose levels and insulin requirement of individuals with type 1 diabetes, especially exercise. 
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For this reason, several recent studies have investigated the function of closed-loop pump 
systems under various exercise conditions. There are two types of closed-loop systems being 
tested currently, single-hormone automated insulin delivery and dual-hormone automated 
glucagon and insulin delivery systems. In a recent study, Castle and colleagues (2018) compared 
the two closed-loop pump systems, predictive low insulin suspension, and traditional open-loop 
pump therapy and their impacts on glycemia during and several hours following in- clinic 
moderate-intensity aerobic exercise. In relation to blood glucose levels with traditional pump 
therapy, predictive low glucose suspension and both closed-loop systems reduced hypoglycemia, 
with the dual-hormone closed-loop pump system producing slightly superior glycemic control. 
However, the addition of glucagon to treatment largely increases the cost and complexity of the 
system and has been observed to induce mild adverse symptoms, such as nausea (Castle et al., 
2018). While the results of this study are promising for the use of closed-loop systems in 
reducing exercise-induced hypoglycemia, the exercise took place in a clinic, which may reduce 
the applicability of results. With a more realistic approach, Breton and colleagues (2017), 
compared the use of an automated insulin delivery closed-loop system to a typical open- loop 
physician monitored system during a five-day ski and snowboard camp for adolescents with type 
1 diabetes. Despite prolonged activity in a cold, high altitude environment, participants using the 
closed-loop system experienced significantly shorter and less frequent episodes of 
hypoglycemia, required fewer carbohydrate supplement treatments, and achieved overall tighter 
glycemic control during and post exercise, as well as throughout the night. Altogether, findings 
from these recent studies are revolutionary in the field of type 1 diabetes management; however, 
there are several limitations to take note of, particularly related accessibility.  
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Limitations and next steps  
When individuals are diagnosed with type 1 diabetes, initial consultation and education 
occurs with an endocrinologist; however, this transmission of essential information often occurs 
in a very expedited manner during a highly stressful time which can be overwhelming for 
individuals, or care takers of individuals with type one diabetes (Silverstein et al., 2005). Further, 
due to the complexity of the condition, additional continued care and extensive education is vital 
to achieving adequate management. In many cases, though, individuals do not have access to a 
team certified professionals, including a dietician, nurse, physician, and mental health care 
provider, to assist them in developing and adapting treatment plans (Peyrot & Rubin, 2008). 
Without this support, many individuals are undereducated about their condition and how to 
successfully manage it.  
Additionally, for many individuals with type 1 diabetes, having access to advanced 
technology, such as CGMs and insulin pumps is limited, and simply obtaining the basic 
necessary supplies for management, including insulin, blood glucose monitors, test strips, and 
needles can be burdensome due to cost. According to a press release from the Centers for 
Disease Control and Prevention (2011), on average annual medical costs for a child with type 1 
diabetes were greater than $9,000 per year. Since 2011, however, costs for managing type 1 
diabetes have skyrocketed, with insulin being the sixth most expensive liquid in the world (Hua 
et al., 2013; Melvin, 2016). With many individuals who have type 1 diabetes struggling to afford 
insulin, a hormone essential to their survival, in addition to their other fundamental medical 
supplies, access to new technologies is severely limited. In order for the promising findings of 
recent research in reducing exercise-induced hypoglycemia to help individuals with type 1 
diabetes achieve adequate glycemic control and improve quality of life, widespread problems 
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regarding accessibility to education and care must first be addressed, which requires greater 
























American Diabetes Association (2015, August 17). Factors affecting blood glucose. Retrieved 
November 21, 2018, from http://www.diabetes.org/living-with-diabetes/treatment-and-
care/blood-glucose-control/factors-affecting-blood-glucose.html  
American Diabetes Association (2017, January 30). Investments in type 1 diabetes research. 
Retrieved November 21, 2018, from http://www.diabetes.org/research-and-practice/we-are-
research-leaders/type-1-research-highlights/investments-in-type-1-diabetes.html 
American Diabetes Association (2018, October 9). Checking your blood glucose. Retrieved 
November 21, 2018, from http://www.diabetes.org/living-with-diabetes/treatment-and-
care/blood-glucose-control/checking-your-blood-glucose.html  
Arif, Z., Neelofar, K., Arfat, M. Y., Zaman, A., Tarannum, A., Parveen, I., Ahmad, S., Khan, M. A., 
Badar, A., & Islam, S. N. (2018). Hyperglycemia induced reactive species trigger structural 
changes in human serum albumin of type 1 diabetic subjects. International Journal of Biological 
Macromolecules, 107, 2141–2149. https://doi.org/10.1016/j.ijbiomac.2017.10.091 
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004). Glucose metabolism and regulation: 
beyond insulin and glucagon. Diabetes Spectrum, 17(3), 183–190. 
https://doi.org/10.2337/diaspect.17.3.183 
Atkinson, M. A. (2012). The pathogenesis and natural history of type 1 diabetes. Cold Spring Harbor 
Perspectives in Medicine, 2(11). https://doi.org/10.1101/cshperspect.a007641 
Basu, R., Johnson, M. L., Kudva, Y. C., & Basu, A. (2014). Exercise, hypoglycemia, and type 1 
diabetes. Diabetes Technology & Therapeutics, 16(6), 331–337. 
https://doi.org/10.1089/dia.2014.0097 
Melvin, A. (2016, May 19). The 10 most expensive liquids in the world [Web long post]. Retrieved 
December 11, 2018, from https://beyondtype1.org/the-10-most-expensive-liquids-in-the-world/  
Breton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, 
L. H., Kovatchev, B. P., & Maahs, D. M. (2017). Closed loop control during intense prolonged 
outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes 
Care, dc170883, 1–7. https://doi.org/10.2337/dc17-0883 
Camacho, R. C., Galassetti, P., Davis, S. N., & Wasserman, D. H. (2005). Glucoregulation during and 
after exercise in health and insulin-dependent diabetes. Exercise and Sport Sciences Reviews, 
33(1), 17–23. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15640716  
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., 
Leitschuh J., Rajhbeharrysingh, U., Senf, B., Sugerman, S. M., Gabo, V., & Jacobs, P. G. (2018). 
Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to 
exercise using wearable sensors. Diabetes Care, 41(7), 1471–1477. https://doi.org/10.2337/dc18-
0228 
Centers for Disease Control and Prevention. (2011, April 27). Medical costs for youth with diabetes 
more than $9,000 a year [Press release]. Retrieved from 
https://www.cdc.gov/media/releases/2011/p0427_youthdiabetes.html  
Giacco, F., Brownlee, M., & Schmidt, A. M. (2010). Oxidative stress and diabetic complications. 
Circulation Research, 107(9), 1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545 
Orton 16 
Hargreaves, M. (2000). Skeletal muscle metabolism during exercise in humans. Clinical and 
Experimental Pharmacology and Physiology, 27(3), 225–228. https://doi.org/10.1046/j.1440-
1681.2000.03225.x 
Howlett, K., Galbo, H., Lorentsen, J., Bergeron, R., Zimmerman-Belsing, T., Bulow, J., Feldt-
Rasmussen, U., Kjaer, M. (1999). Effect of adrenaline on glucose kinetics during exercise in 
adrenalectomised humans. J Physiol, 519 (Pt 3): 911–921. https://www.doi.org/10.1111/j.1469-
7793.1999.0911n.x  
Hua, X., Carvalho, N., Tew, M., Huang, E. S., Herman, W. H., & Clarke, P. (2016). Expenditures and 
prices of antihyperglycemic medications in the United States: 2002-2013. JAMA, 315(13), 1400–
1402. https://doi.org/10.1001/jama.2016.0126 
Jensen, V. F. H., Bøgh, I. B., & Lykkesfeldt, J. (2014). Effect of insulin-induced hypoglycaemia on 
the central nervous system: evidence from experimental studies. Journal of Neuroendocrinology, 
26(3), 123–150. https://doi.org/10.1111/jne.12133 
Jones, T. W., Porter, P., Sherwin, R. S., Davis, E. A., O’Leary, P., Frazer, F., Byrne, G., Stick, S., & 
Tamborlane, W. V. (1998). Decreased epinephrine responses to hypoglycemia during sleep. New 
England Journal of Medicine, 338(23), 1657–1662. 
https://doi.org/10.1056/NEJM199806043382303 
Krause, M. P., Al-Sajee, D., D’Souza, D. M., Rebalka, I. A., Moradi, J., Riddell, M. C., & Hawke, T. 
J. (2013). Impaired macrophage and satellite cell infiltration occurs in a muscle-specific fashion 
following injury in diabetic skeletal muscle. PLOS ONE, 8(8), 1–13. 
https://doi.org/10.1371/journal.pone.0070971 
Maggio, A., Ferrari, S., Kraenzlin, M., Marchand, L.M., Schwitzgebel, V., Beghetti, M., Rizzoli, R., 
& Farpour-Lambert, N. (2010). Decreased bone turnover in children and adolescents with well 
controlled type 1 diabetes. Journal of pediatric endocrinology & metabolism, 23(7), 697–707. 
https://doi.org/10.1515/JPEM.2010.23.7.697  
Mayo Clinic (2017, August 7). Type 1 diabetes. Retrieved from https://www.mayoclinic.org/diseases-
conditions/type-1-diabetes/symptoms-causes/syc-20353011 
Mianowska, B., Fendler, W., Szadkowska, A., Baranowska, A., Grzelak-Agaciak, E., Sadon, J., 
Keenen, H., & Mlynarski, W. (2011). HbA1c levels in schoolchildren with type 1 diabetes are 
seasonally variable and dependent on weather conditions. Diabetologia, 54(4), 749–756. 
https://doi.org/10.1007/s00125-010-2013-4 
National Diabetes Education Initiative (2016, January). Diabetes management guidelines. Retrieved 
November 21, 2018, from http://www.ndei.org/ADA-diabetes-management-guidelines-self-
monitoring-blood-glucose-SMBG-insulin.aspx.html  
Northam, E. A., Anderson, P. J., Jacobs, R., Hughes, M., Warne, G. L., & Werther, G. A. (2001). 
Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes 
Care, 24(9), 1541–1546. https://doi.org/10.2337/diacare.24.9.1541 
Parajuli, A., Liu, C., Li, W., Gu, X., Lai, X., Pei, S., Price, C., You, L., Lu, X. L., & Wang, L. (2015). 
Bone’s responses to mechanical loading are impaired in type 1 diabetes. Bone, 81, 152–160. 
https://doi.org/10.1016/j.bone.2015.07.012 
Orton 17 
Paty, B. W. (2015). The role of hypoglycemia in cardiovascular outcomes in diabetes. Canadian 
Journal of Diabetes, 39, S155–S159. https://doi.org/10.1016/j.jcjd.2015.09.009 
Peyrot, M., & Rubin, R. R. (2008). Access to diabetes self-management education. The Diabetes 
Educator, 34(1), 90–97. https://doi.org/10.1177/0145721707312399 
Raman, P. G. (2017). Central nervous system control of glucose homeostasis. Open Journal of 
Endocrine and Metabolic Diseases, 7(12), 227–234. https://doi.org/10.4236/ojemd.2017.712020 
Raghupathy, P. (2015). Diabetic ketoacidosis in children and adolescents. Indian Journal of 
Endocrinology and Metabolism, 19(Suppl 1), S55–S57. https://doi.org/10.4103/2230-
8210.155403 
Riddell, M. C., Gallen, I. W., Smart, C. E., Taplin, C. E., Adolfsson, P., Lumb, A. N., Kowalski, A., 
Rabasa-Lhoret, R., McCrimmon, R. J., Hume, C., Annan, F., Fournier, P. A., Graham, C., Bode, 
B., Galassetti, P., Jones, T. W., Millán, I. S., Heise, T., Peters, A. L., Petz, A., & Laffel, L. M. 
(2017). Exercise management in type 1 diabetes: a consensus statement. The Lancet Diabetes & 
Endocrinology, 5(5), 377–390. https://doi.org/10.1016/S2213-8587(17)30014-1 
Rooijackers, H. M. M., Wiegers, E. C., Tack, C. J., van der Graaf, M., & de Galan, B. E. (2016). 
Brain glucose metabolism during hypoglycemia in type 1 diabetes: insights from functional and 
metabolic neuroimaging studies. Cellular and Molecular Life Sciences, 73, 705–722. 
https://doi.org/10.1007/s00018-015-2079-8 
Rosenfeld, L. (2002). Insulin: discovery and controversy. Clinical Chemistry, 48(12), 2270–2288. 
Retrieved from http://clinchem.aaccjnls.org/content/48/12/2270.long  
Scarlett, J. M., & Schwartz, M. W. (2015). Gut-brain mechanisms controlling glucose homeostasis. 
F1000Prime Reports, 7. https://doi.org/10.12703/P7-12 
Silverstein, J., Klingensmith, G., Copeland, K., Plotnick, L., Kaufman, F., Laffel, L., Beeb, L., Grey, 
M., Anderson, B., Holzmeister, L. A., & Clark, N. (2005). Care of children and adolescents with 
type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care, 28(1), 186–
212. https://doi.org/10.2337/diacare.28.1.186 
Singh, R. (2002). The Importance of Exercise as a Therapeutic Agent. The Malaysian Journal of 
Medical Sciences, 9(2), 7–16. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406202/  
Stehno-Bittel, L. (2012). Organ-based response to exercise in type 1 diabetes. ISRN Endocrinology, 
2012. https://doi.org/10.5402/2012/318194 
Subramanian, S., Baidal, D., Skyler, J. S., & Hirsch, I. B. (2016, November 16). The management of 
type 1 diabetes. In De De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. 
Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK279114/ 
Tamborlane, W. V., Bonfig, W., & Boland, E. (2001). Recent advances in treatment of youth with 
Type 1 diabetes: better care through technology. Diabetic Medicine, 18(11), 864–870. 
https://doi.org/10.1046/j.1464-5491.2001.00626.x 
Tanoli, T., Puente, E. C., & Fisher, S. J. (2011). Hypoglycemia and the central nervous system. 
Hypoglycemia and the Central Nervous System. Retrieved from 
https://www.touchendocrinology.com/articles/hypoglycemia-and-central-nervous-system 
Orton 18 
Tansey M. J., Tsalikian E., Beck R. W., Mauras N., Buckingham B. A., Weinzimer S.A., Janz, K. F. 
Kollman, C., Xing, D., Ruedy, K. J., Steffes, M. W., Borland, T. M., Singh, R. J., & Tamborlane, 
W. J. (2006). The effects of aerobic exercise on glucose and counterregulatory hormone 
concentrations in children with type 1 diabetes. Diabetes Care. 29(1), 20–25. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396943/pdf/nihms39253.pdf  
Turner, D., Luzio, S., Gray, B. J., Dunseath, G., Rees, E. D., Kilduff, L. P., Campbell, M. D., West, 
D. J., Bain, S. C., & Bracken, R. M. (2015). Impact of single and multiple sets of resistance 
exercise in type 1 diabetes. Scandinavian Journal of Medicine & Science in Sports, 25(1), e99–
e109. https://doi.org/10.1111/sms.12202 
Warburton, D. E. R., Nicol, C. W., & Bredin, S. S. D. (2006). Health benefits of physical activity: the 
evidence. Canadian Medical Association Journal, 174(6), 801–809. 
https://doi.org/10.1503/cmaj.051351 
West, D. J., Morton, R. D., Bain, S. C., Stephens, J. W., & Bracken, R. M. (2010). Blood glucose 
responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals 
with type 1 diabetes. Journal of Sports Sciences, 28(7), 781–788. 
https://doi.org/10.1080/02640411003734093 
West, D. J., Stephens, J. W., Bain, S. C., Kilduff, L. P., Luzio, S., Still, R., & Bracken, R. M. (2011). 
A combined insulin reduction and carbohydrate feeding strategy 30 min before running best 
preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 
diabetes mellitus. Journal of Sports Sciences, 29(3), 279–289. 
https://doi.org/10.1080/02640414.2010.531753 
Wilcox, G. (2005). Insulin and insulin resistance. Clinical Biochemist Reviews, 26(2), 19–39. 
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1204764/  
Yardley, J. E., Kenny, G. P., Perkins, B. A., Riddell, M. C., Malcolm, J., Boulay, P., Boulay, P., 
Khandwala, F., & Sigal, R. J. (2012). Effects of performing resistance exercise before versus 
after aerobic exercise on glycemia in type 1 diabetes. Diabetes Care, 35(4), 669–675. 
https://doi.org/10.2337/dc11-1844 
Yardley, J. E., Kenny, G. P., Perkins, B. A., Riddell, M. C., Balaa, N., Malcolm, J., Boulay, P., 
Khandwala, F., & Sigal, R. J. (2013). Resistance versus aerobic exercise: acute effects on 
glycemia in type 1 diabetes. Diabetes Care; Alexandria, 36(3), 537–542. 
Yang, S.-W., Park, K.-H., & Zhou, Y.-J. (2016). The impact of hypoglycemia on the cardiovascular 
system: physiology and pathophysiology. Angiology, 67(9), 802–809. 
https://doi.org/10.1177/0003319715623400 
You, W. P., & Henneberg, M. (2016). Type 1 diabetes prevalence increasing globally and regionally: 
the role of natural selection and life expectancy at birth. BMJ Open Diabetes Research and Care, 
4(e000161), 1–7. https://doi.org/10.1136/bmjdrc-2015-000161 
 
